Literature DB >> 23607980

Hermansky-Pudlak syndrome (HPS5) in a nonagenarian.

Alexander L Ringeisen1, Lisa A Schimmenti, James G White, Cheri Schoonveld, C Gail Summers.   

Abstract

Hermansky-Pudlak syndrome (HPS) is an autosomal-recessive disorder clinically characterized by oculocutaneous albinism, bleeding diatheses, and lysosomal accumulation of ceroid lipofuscin, which in some cases may cause granulomatous colitis and pulmonary fibrosis. Any of these complications could result in a shortened life span for patients with HPS. We report a 92-year-old man with HPS 5 who, to our knowledge, is the oldest patient with HPS documented in the literature. This report highlights the importance of typing HPS to counsel patients regarding disease prognosis.
Copyright © 2013 American Association for Pediatric Ophthalmology and Strabismus. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23607980     DOI: 10.1016/j.jaapos.2013.02.002

Source DB:  PubMed          Journal:  J AAPOS        ISSN: 1091-8531            Impact factor:   1.220


  3 in total

1.  Posterior staphyloma in oculocutaneous albinism: another possible cause of reduced visual acuity.

Authors:  Susan Lee; Lisa A Schimmenti; Richard A King; Murray Brilliant; Jennifer L Anderson; Cheri Schoonveld; C Gail Summers
Journal:  J AAPOS       Date:  2015-12       Impact factor: 1.220

2.  Cellular and molecular defects in a patient with Hermansky-Pudlak syndrome type 5.

Authors:  Joshi Stephen; Tadafumi Yokoyama; Nathanial J Tolman; Kevin J O'Brien; Elena-Raluca Nicoli; Brian P Brooks; Laryssa Huryn; Steven A Titus; David R Adams; Dong Chen; William A Gahl; Bernadette R Gochuico; May Christine V Malicdan
Journal:  PLoS One       Date:  2017-03-15       Impact factor: 3.240

3.  Hermansky-Pudlak syndrome: Mutation update.

Authors:  Marjan Huizing; May C V Malicdan; Jennifer A Wang; Hadass Pri-Chen; Richard A Hess; Roxanne Fischer; Kevin J O'Brien; Melissa A Merideth; William A Gahl; Bernadette R Gochuico
Journal:  Hum Mutat       Date:  2020-01-23       Impact factor: 4.700

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.